Citations

Clear

4610 citation(s) found for "Lu, Brian".

Teaching Neuro Images : “Pancake-like” gadolinium enhancement suggests compressive myelopathy due to spondylosis
Flanagan, Eoin P. , Marsh, Richard W., Weinshenker, Brian G. , Flanagan, E P , Weinshenker, Brian G

Mayo Clinic

Neurology | May 20, 2013 | Volume: 80 | Issue: 21 | Pages: No page available

10.1212/wnl.0b013e318293e346 | PMID 23690303 Get It

Safety of Sports for Athletes With Implantable Cardioverter-Defibrillators
Lampert, Rachel , Olshansky, Brian , Heidbüchel, Hein , Lawless, Christine E., Saarel, Elizabeth V. , Ackerman, Michael J. , Calkins, Hugh , Maron, Barry J. , Scheinman, Melvin M. , Wilkoff, Bruce L. , Zipes, Douglas P. , Berul, Charles I. , Cheng, Alan , Law, Ian H. , Loomis, Michele, Barth, Cheryl , Dziura, James , Cannom, David S. , Estes, N.A. Mark , Link, Mark S. , Marcus, Gregory M. , Brandt, Cynthia , Li, Fangyong , Olshansky, Brian , Law, Ian H , Zipes, Douglas P

Mayo Clinic

Circulation | May 20, 2013 | Volume: 127 | Issue: 20 | Pages: 2021-2030

10.1161/circulationaha.112.000447 | PMID 23690453 Get It

Background— The risks of sports participation for implantable cardioverter-defibrillator (ICD) patients are unknown. Methods and Results— Athletes with ICDs (age, 10–60 years) participating in organized (n=328) or high-risk (n=44) sports were recruited. Sports-related and clinical data were obtained by phone interview and medical records. Follow-up occurred every 6 months. ICD shock data and clinical outcomes were adjudicated by 2 electrophysiologists. Median age was 33 years (89 subjects <20 years of age); 33% were female. Sixty were competitive athletes (varsity/junior varsity/traveling team). A pre-ICD history of ventricular arrhythmia was present in 42%. Running, basketball, and soccer were the most common sports. Over a median 31-month (interquartile range, 21–46 months) follow-up, there were no occurrences of either primary end point—death or resuscitated arrest or arrhythmia- or shock-related injury—during sports. There were 49 shocks in 37 participants (10% of study population) during competition/practice, 39 shocks in 29 participants (8%) during other physical activity, and 33 shocks in 24 participants (6%) at rest. In 8 ventricular arrhythmia episodes (device defined), multiple shocks were received: 1 at rest, 4 during competition/practice, and 3 during other physical activity. Ultimately, the ICD terminated all episodes. Freedom from lead malfunction was 97% at 5 years (from implantation) and 90% at 10 years. Conclusions— Many athletes with ICDs can engage in vigorous and competitive sports without physical injury or failure to terminate the arrhythmia despite the occurrence of both inappropriate and appropriate shocks. These data provide a basis for more informed physician and patient decision making in terms of sports participation for athletes with ICDs.
Level IIB lymph node metastasis in laryngeal and hypopharyngeal squamous cell carcinoma: Single‐institution case series and review of the literature
Gross, Brian C., Olsen, Steven M., Lewis, Jean E., Kasperbauer, Jan L. , Moore, Eric J. , Olsen, Kerry D., Price, Daniel L. , Price, Daniel L

Mayo Clinic

The Laryngoscope | May 20, 2013 | Volume: 123 | Issue: 12 | Pages: 3032-3036

10.1002/lary.24198 | PMID 23686866 Get It

Objectives/HypothesisTo determine the incidence of level IIB lymph node metastasis in patients with laryngeal or hypopharyngeal squamous cell carcinoma and to evaluate the need for elective and therapeutic neck dissection of level IIB.Study DesignRetrospective cohort study and review of the literature.MethodsPatients with laryngeal or hypopharyngeal squamous cell carcinoma (N = 65) were primarily treated with surgery at Mayo Clinic (Rochester, Minnesota) from 2004 through 2010. Neck dissection specimens were analyzed by a pathologist, and metastases to level IIB were reported. In addition, 18 previously published studies, totaling 1,114 neck dissections, were reviewed.ResultsLevel IIB lymph node metastases were present in 4% and 17% of elective and therapeutic neck dissections, respectively. Ipsilateral IIB metastasis was more common than contralateral IIB metastasis in elective and therapeutic neck dissection specimens. Level IIB lymph node metastasis was not significantly associated with level IIA nodal metastasis, level III nodal metastasis, clinical primary tumor stage, clinical nodal stage, or pathologic confirmation of extracapsular spread in either laryngeal or hypopharyngeal squamous cell carcinoma.ConclusionsThe rate of occult IIB metastasis in laryngeal and hypopharyngeal squamous cell carcinoma is exceedingly low. In a clinically node‐negative case, the ipsilateral and contralateral level IIB nodal packet should not be dissected. For clinically node‐positive cases, ipsilateral level IIB dissection should be performed; contralateral IIB dissection should be performed only when indicated.Level of Evidence4. Laryngoscope, 123:3032–3036, 2013
Adaptive adjustment of the randomization ratio using historical control data
Hobbs, Brian P. , Carlin, Bradley P. , Sargent, Daniel J. , Sargent, Daniel J

Mayo Clinic

Clinical Trials | May 20, 2013 | Volume: 10 | Issue: 3 | Pages: 430-440

10.1177/1740774513483934 | PMID 23690095 Get It

Background Prospective trial design often occurs in the presence of ‘acceptable’ historical control data. Typically, these data are only utilized for treatment comparison in a posteriori retrospective analysis to estimate population-averaged effects in a random-effects meta-analysis. Purpose We propose and investigate an adaptive trial design in the context of an actual randomized controlled colorectal cancer trial. This trial, originally reported by Goldberg et al., succeeded a similar trial reported by Saltz et al., and used a control therapy identical to that tested (and found beneficial) in the Saltz trial. Methods The proposed trial implements an adaptive randomization procedure for allocating patients aimed at balancing total information (concurrent and historical) among the study arms. This is accomplished by assigning more patients to receive the novel therapy in the absence of strong evidence for heterogeneity among the concurrent and historical controls. Allocation probabilities adapt as a function of the effective historical sample size (EHSS), characterizing relative informativeness defined in the context of a piecewise exponential model for evaluating time to disease progression. Commensurate priors are utilized to assess historical and concurrent heterogeneity at interim analyses and to borrow strength from the historical data in the final analysis. The adaptive trial’s frequentist properties are simulated using the actual patient-level historical control data from the Saltz trial and the actual enrollment dates for patients enrolled into the Goldberg trial. Results Assessing concurrent and historical heterogeneity at interim analyses and balancing total information with the adaptive randomization procedure lead to trials that on average assign more new patients to the novel treatment when the historical controls are unbiased or slightly biased compared to the concurrent controls. Large magnitudes of bias lead to approximately equal allocation of patients among the treatment arms. Using the proposed commensurate prior model to borrow strength from the historical data, after balancing total information with the adaptive randomization procedure, provides admissible estimators of the novel treatment effect with desirable bias-variance trade-offs. Limitations Adaptive randomization methods in general are sensitive to population drift and more suitable for trials that initiate with gradual enrollment. Balancing information among study arms in time-to-event analyses is difficult in the presence of informative right-censoring. Conclusions The proposed design could prove important in trials that follow recent evaluations of a control therapy. Efficient use of the historical controls is especially important in contexts where reliance on preexisting information is unavoidable because the control therapy is exceptionally hazardous, expensive, or the disease is rare.
Level IIB lymph node metastasis in oropharyngeal squamous cell carcinoma
Gross, Brian C., Olsen, Steven M., Lewis, Jean E., Kasperbauer, Jan L. , Moore, Eric J. , Olsen, Kerry D., Price, Daniel L. , Price, Daniel L

Mayo Clinic

The Laryngoscope | May 17, 2013 | Volume: 123 | Issue: 11 | Pages: 2700-2705

10.1002/lary.24129 | PMID 23686577 Get It

Objectives/HypothesisTo determine the incidence of level IIB lymph node metastasis in patients with oropharyngeal squamous cell carcinoma (OPSCC) and to evaluate the necessity of level IIB dissection for elective and therapeutic neck dissections.Study DesignRetrospective cohort study.MethodsPatients with OPSCC (N = 348) were surgically managed at our institution from 2004 through 2010. Neck dissection specimens were reviewed by a pathologist, and level IIB metastases were analyzed with respect to clinical and pathologic data.ResultsLevel IIB lymph node metastases were present in 2.5% and 25% of elective and therapeutic neck dissections, respectively. Level IIA metastasis, clinical tumor stage, clinical nodal stage, extracapsular spread, and primary tumor location in the tonsil were significantly associated with level IIB metastasis.ConclusionsThis study uniquely demonstrated a statistically significant association between clinical tumor stage and tonsil subsite with level IIB metastasis in OPSCC. Considering the predicted incidence of nodal metastasis, we conclude that level IIB neck dissection can be omitted in early stage (T1 or T2) clinically node negative (cN0) OPSCC. In patients with a cN0 neck and advanced OPSCC (T3 or T4), primary tumor in the tonsil, or ipsilateral clinically node positive (cN+) and contralateral cN0 neck, level IIB dissection should be considered. Level IIB dissection should be performed routinely in patients with cN+ OPSCC.Level of Evidence4. Laryngoscope, 123:2700–2705, 2013
Overall survival advantage with partial nephrectomy: A bias of observational data?
Shuch, Brian , Lai, Julie , Vourganti, Srinivas , Kim, Simon P. , Dick, Andrew W., Chow, Wong‐Ho , Saigal, Chris, Project, the Urologic Diseases in America, Hanley, Janet M. , Setodji, Claude Messan , Project, the Urologic Diseases in America

Mayo Clinic

Cancer | May 14, 2013 | Volume: 119 | Issue: 16 | Pages: 2981-2989

10.1002/cncr.28141 | PMID 23674264 Get It

BACKGROUNDPartial nephrectomy (PN) and radical nephrectomy (RN) are standard treatments for a small renal mass. Retrospective studies suggest an overall survival (OS) advantage, however a randomized phase 3 trial suggests otherwise. The effects of both surgical modalities on OS were evaluated compared with controls.METHODSA matched cohort study was performed using the Surveillance, Epidemiology, and End Results (SEER)‐Medicare dataset. Individuals treated with PN or RN for localized renal cell carcinoma (RCC) measuring ≤4 cm were compared with 2 control groups (non–muscle‐invasive bladder cancer (BCC) and noncancer controls (NCC). Using a greedy algorithm, RCC groups were matched with controls by demographics and comorbidities. OS for surgical groups and controls were compared. The cause of death was evaluated for cancer groups when differences in OS were noted.RESULTSPatients undergoing PN and RN were matched with controls. All cancer groups had >95% 10‐year cancer‐specific survival (CSS). Median OS was similar between RN (9.05 years) and BCC (8.67 years; P = .067) and NCC (8.77 years; P = .49). Median OS was improved for PN (10.45 years) compared with BCC (8.75 years; P<.001) and NCC controls (8.76 years; P<.001). A multivariate Cox hazards model demonstrated that PN improved OS compared with NCC (hazard ratio, 1.257; P<.001) and BCC (hazard ratio, 1.364; P<.001).CONCLUSIONSRN patients had similar OS compared with controls, suggesting that this treatment modality does not compromise survival. Patients undergoing PN had improved OS compared with controls, suggesting possible selection bias. The apparent survival advantage conferred by PN in SEER‐Medicare case series is likely the result of selection bias involving unmeasured confounders. Cancer 2013;119:2981—2989. © 2013 American Cancer Society.
ANO5‐muscular dystrophy: clinical, pathological and molecular findings
Liewluck, Teerin , Winder, Thomas , Dimberg, Elliot L., Heppelmann, Carrie J. , Wang, Y., Bergen, H. Robert, Milone, Margherita , Crum, Brian A. , Liewluck, T

Mayo Clinic

European Journal of Neurology | May 12, 2013 | Volume: 20 | Issue: 10 | Pages: 1383-1389

10.1111/ene.12191 | PMID 23663589 Get It

Background and purposeAnoctamin 5 (ANO5) is a putative intracellular calcium‐activated chloride channel. Recessive mutations in ANO5 cause primary skeletal muscle disorders (limb‐girdle muscular dystrophy 2L and distal muscular dystrophy), which are phenotypically similar to dysferlinopathy, a muscular dystrophy due to dysferlin‐encoding gene (DYSF) mutations.MethodsThis study reports the phenotype and genotype of seven unrelated patients with ANO5‐muscular dystrophy.ResultsThree patients had amyloid deposition in muscle and two had cardiac involvement. An additional patient without skeletal muscle amyloidosis had cardiac involvement with septal hypokinesis and supraventricular tachycardia requiring ablation. Amyloid subtyping using laser capture microdissection and mass spectrometry‐based proteomic analysis did not identify ANO5 or any fragment of ANO5 in the amyloid deposits, but detected other known amyloidogenic proteins. Three patients had myotonic discharges without clinical myotonia. Four ANO5 mutations are novel, including a heterozygous 0.4 Mb deletion involving the entire ANO5 gene.ConclusionsThe results of the present study suggest that ANO5 mutations can be associated with amyloid deposition in muscle, but the nature of the amyloid deposits remains indeterminate, as does their relationship with cardiac involvement. ANO5 analysis should be considered in cases of muscle amyloid deposition of indeterminate etiology. Electrical myotonia can accompany ANO5‐muscular dystrophy.
TNFRSF1A polymorphisms and MS
Weinshenker, Brian, Tienari, Pentti J. , Weinshenker, Brian G. , Weinshenker, Brian G

Mayo Clinic

Neurology | April 27, 2013 | Volume: 80 | Issue: 22 | Pages: 2002-2003

10.1212/wnl.0b013e318294b4ab | PMID 23624561 Get It

A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B‐cell non‐Hodgkin lymphoma
Wiseman, Gregory A., Maurer, Matthew J. , Micallef, Ivana N. , Nowakowski, Grzegorz S. , Ansell, Stephen M. , Inwards, David J. , Porrata, Luis F. , Link, Brian K. , Johnston, Patrick B. , Allmer, Cristine, Asmann, Yan W. , Ballas, Zuhair K. , Smith, Brian J., Weiner, George J. , Witzig, Thomas E. , Habermann, Thomas M. , Colgan, Joseph P. , Zent, Clive S. , Shanafelt, Tait D. , Gupta, Mamta , Smith, Brian J., Maurer, Matthew , Link, Brian K , Weiner, George

Mayo Clinic

American Journal of Hematology | April 26, 2013 | Volume: 88 | Issue: 7 | Pages: 589-593

10.1002/ajh.23460 | PMID 23619698 Get It

Radioimmunotherapy (RIT) for relapsed indolent non‐Hodgkin lymphoma produces overall response rates (ORR) of 80% with mostly partial remissions. Synthetic CpG oligonucleotides change the phenotype of malignant B‐cells, are immunostimulatory, and can produce responses when injected intratumorally and combined with conventional radiation. In this phase I trial, we tested systemic administration of both CpG and RIT. Eligible patients had biopsy‐proven previously treated CD20+ B‐cell NHL and met criteria for RIT. Patients received rituximab 250 mg/m2 days 1,8, and 15; 111In‐ibritumomab tiuxetan days 1, 8; CpG 7909 days 6, 13, 20, 27; and 0.4 mCi/kg of 90Y‐ibritumomab tiuxetan day 15. The doses of CpG 7909 tested were 0.08, 0.16, 0.32 (six patients each) and 0.48 mg/kg (12 patients) IV over 2 hr without dose limiting toxicity. The ORR was 93% (28/30) with 63% (19/30) complete remission (CR); median progression free survival of 42.7 months (95% CI 18‐NR); and median duration of response (DR) of 35 months (4.6–76+). Correlative studies demonstrated a decrease in IL10 and TNFα, and an increase in IL1β, in response to therapy. CpG 7909 at a dose of 0.48 mg/kg is safe with standard RIT and produces a high CR rate and long DR; these results warrant confirmation. Am. J. Hematol. 88:589–593, 2013. © 2013 Wiley Periodicals, Inc.
Surgical anatomy of hand allotransplantation
Carlsen, Brian T. , Al‐Mufarrej, Faisal, Moran, Steven L.

Mayo Clinic

Clinical Anatomy | April 23, 2013 | Volume: 26 | Issue: 5 | Pages: 578-583

10.1002/ca.22229 | PMID 23609942 Get It

The hand is the most refined anatomical terminal device known and the leading edge of the sensorium. Further, the hand is second only to the face in terms of visibility and is a vitally important aspect aesthetic and body image. Hand amputation represents a devastating loss of function and independence. Restoring function after limb loss is a challenge and traditionally includes autologous methods and prosthetics. In the last 15 years, hand transplantation has become a viable option for select patients. Clin. Anat. 26:578–583, 2013. © 2013 Wiley Periodicals, Inc.